{"id":16864,"date":"2025-10-14T13:00:00","date_gmt":"2025-10-14T13:00:00","guid":{"rendered":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/"},"modified":"2025-10-14T13:00:00","modified_gmt":"2025-10-14T13:00:00","slug":"%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85","status":"publish","type":"post","link":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/","title":{"rendered":"\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3"},"content":{"rendered":"<p class=\"prntac\">\n<\/p><p>                    <span>DESTINY<\/span>-Breast11\u4e0eDESTINY-Breast05\u4e24\u9879\u7814\u7a76\u5165\u9009\u4e3b\u5e2d\u7814\u8ba8\u4f1a\uff08Presidential Symposium\uff09\uff0c\u51f8\u663e\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u5728\u6cbb\u7597HER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\u4e2d\u7684\u6f5c\u5728\u4ef7\u503c\n                <\/p>\n<p class=\"prntac\">\n                  TROPION-Breast02\u7814\u7a76\u6570\u636e\u5c06\u5c55\u793a\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u5728\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\u8fd9\u4e00\u6700\u5177\u4fb5\u88ad\u6027\u7684\u4e73\u817a\u764c\u5206\u578b\u4e2d\u7684\u6cbb\u7597\u6f5c\u529b\n                <\/p>\n<p class=\"prntac\">\n                  POTOMAC\u7814\u7a76\u7684\u65e0\u75c5\u751f\u5b58\u671f\u6570\u636e\u4e0eMATTERHORN\u7814\u7a76\u7684\u751f\u5b58\u671f\u6570\u636e\u5c06\u5c55\u793a\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u5728\u65e9\u671f\u8180\u80f1\u764c\u4e0e\u80c3\u764c\u6cbb\u7597\u4e2d\u7684\u83b7\u76ca\n                <\/p>\n<p>\n                  <span class=\"legendSpanClass\">\u4e0a\u6d77<\/span><br \/>\n                  <span class=\"legendSpanClass\">2025\u5e7410\u670814\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212;\u00a0\u963f\u65af\u5229\u5eb7\u5c06\u4e8e2025\u5e7410\u670817\u65e5\u81f321\u65e5\u53ec\u5f00\u7684\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\u4e0a\uff0c\u51ed\u501f\u2f8f\u4e1a\u9886\u5148\u7684\u591a\u6837\u5316\u4ea7\u54c1\u4e0e\u7ba1\u7ebf\u5e03\u5c40\u7684\u5168\u65b0\u7814\u7a76\u6570\u636e\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u5176\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u683c\u5c40\u7684\u96c4\u5fc3\u58ee\u5fd7\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p>\n                    <a href=\"https:\/\/mma.prnewswire.com\/media\/2795662\/image.html\" target=\"_blank\" rel=\"noopener\"><\/a><\/p>\n<p>                    \n                  <\/p>\n<\/div>\n<p>\n                  <span>\u672c\u6b21\u5927\u4f1a\u4e0a<\/span>\uff0c\u963f\u65af\u5229\u5eb7\u5c06\u516c\u5e03\u903e95\u9879\u6458\u8981\uff0c\u6db5\u76d69\u6b3e\u5df2\u83b7\u5f97\u6279\u51c6\u836f\u7269\u53ca9\u6b3e\u6f5c\u5728\u65b0\u836f\uff0c\u5305\u62ec2\u9879\u5165\u9009<span>\u91cd\u8981<\/span>\u4e3b\u5e2d\u7814\u8ba8\u4f1a\uff08Presidential Symposium\uff09\u7684\u6458\u8981\u4ee5\u53ca26\u9879\u53e3\u5934\u62a5\u544a\u3002<\/p>\n<p>\u5176\u4e2d\u4e3b\u8981\u4eae\u70b9\u5305\u62ec\uff1a<\/p>\n<p>                    DESTINY-Breast11\uff1a\u8bc4\u4f30\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u5e8f\u8d2fTHP\u65b9\u6848\uff08\u7d2b\u6749\u9187\u3001\u66f2\u59a5\u73e0\u5355\u6297\u53ca\u5e15\u59a5\u73e0\u5355\u6297\uff09\u7528\u4e8e\u9ad8\u98ce\u9669HER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\u65b0\u8f85\u52a9\u6cbb\u7597\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4e3b\u5e2d\u7814\u8ba8\u4f1a1\uff0c\u6458\u8981#291O\uff09\u3002<\/p>\n<p>                    DESTINY-Breast05\uff1a\u8bc4\u4f30\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u7528\u4e8eHER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\uff08\u65b0\u8f85\u52a9\u6cbb\u7597\u540e\u5b58\u5728\u6b8b\u7559\u6d78\u6da6\u75c5\u7076\u5e76\u5177\u6709\u9ad8\u590d\u53d1\u98ce\u9669\uff09\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4e3b\u5e2d\u7814\u8ba8\u4f1a1\uff0c\u6458\u8981#LBA1\uff09\u3002\u00a0<\/p>\n<p>                    TROPION-Breast02\uff1a\u8bc4\u4f30\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u7528\u4e8e\u4e00\u7ebf\u6cbb\u7597\u65e0\u6cd5\u63a5\u53d7\u514d\u75ab\u6cbb\u7597\u7684\u5c40\u90e8\u590d\u53d1\u6027\u4e0d\u53ef\u624b\u672f\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA21\uff09\u3002<\/p>\n<p>                    POTOMAC<br \/>\n                    \uff1a\u8bc4\u4f30\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408\u5361\u4ecb\u82d7\uff08BCG\uff09\u8bf1\u5bfc\u4e0e\u7ef4\u6301\u6cbb\u7597\uff0c\u7528\u4e8e\u9ad8\u5371\u975e\u808c\u5c42\u6d78\u6da6\u6027\u8180\u80f1\u764c\uff08NMIBC\uff09\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA108\uff09\u3002<\/p>\n<p>                    MATTERHORN\uff1a\u516c\u5e03III\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u6700\u7ec8\u603b\u751f\u5b58\u671f\uff08OS\uff09\u7ed3\u679c\uff0c\u8bc4\u4f30\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408FLOT\u5316\u7597\u4f5c\u4e3a\u53ef\u5207\u9664\u7684\u65e9\u671f\u548c\u5c40\u90e8\u665a\u671f\u7684\u80c3\u548c\u80c3\u2edd\u7ba1\u7ed3\u5408\u90e8\u817a\u764c\uff08GEJ\uff09\u60a3\u8005\u56f4\u624b\u672f\u671f\u6cbb\u7597\u4e2d\u7684\u4e34\u5e8a\u83b7\u76ca\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA81\uff09\u3002<\/p>\n<p>\u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\u3001\u5168\u7403\u80bf\u7624\u7814\u53d1\u8d1f\u8d23\u4eba\u9ad8\u4e66\u74a8\uff08Susan Galbraith\uff09\u8868\u793a\uff1a&#8221;\u6211\u4eec\u6b63\u52a0\u901f\u63a8\u8fdb\u591a\u5143\u521b\u65b0\u7597\u6cd5\u7ba1\u7ebf\uff0c\u4ee5\u53d8\u9769\u4e73\u817a\u764c\u60a3\u8005\u7684\u6cbb\u7597\u683c\u5c40\u3002\u5728\u672c\u5c4aESMO\u5927\u4f1a\u4e0a\uff0c\u6211\u4eec\u5c06\u516c\u5e03TROPION-Breast02\u3001DESTINY-Breast11\u548cDESTINY-Breast05\u7814\u7a76\u7684\u6570\u636e\u548c\u91cd\u8981\u8fdb\u5c55\u3002\u540c\u65f6\uff0c\u6211\u4eec\u4e5f\u5c06\u5c55\u793a\u65b0\u4e00\u4ee3\u6f5c\u5728\u6297\u80bf\u7624\u65b0\u836f\u7684\u6570\u636e\uff0c\u5305\u62ecsaruparib\u8054\u5408\u65b0\u578b\u6fc0\u7d20\u7597\u6cd5\u7528\u4e8e\u524d\u5217\u817a\u764c\u9886\u57df\uff0c\u9776\u5411\u53f6\u9178\u53d7\u4f53\u7684\u6297\u4f53\u5076\u8054\u836f\u7269torvu-sam\u7528\u4e8e\u5375\u5de2\u764c\u9886\u57df\uff0c\u4ee5\u53carilvegostomig\u7528\u4e8e\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u9886\u57df\u3002&#8221;<\/p>\n<p>\u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\uff0c\u80bf\u7624\u4e1a\u52a1\u8d1f\u8d23\u4ebaDave Fredrickson\u8868\u793a\uff1a&#8221;\u6211\u4eec\u4e1a\u754c\u9886\u5148\u7684\u80bf\u7624\u4ea7\u54c1\u7ec4\u5408\u5728\u672c\u6b21ESMO\u6301\u7eed\u5c55\u73b0\u5f3a\u52b2\u52bf\u5934\uff0c\u9996\u6b21\u516c\u5e03\u4e86\u56db\u9879\u5173\u952e\u7814\u7a76\u7684\u6570\u636e\u3002\u5176\u4e2d\uff0c\u4e0d\u4ec5\u6709\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u548c\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u5728\u4e73\u817a\u764c\u9886\u57df\u7684\u91cd\u5927\u8fdb\u5c55\uff0c\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u7684POTOMAC\u8bd5\u9a8c\u7ed3\u679c\u4e5f\u8bc1\u660e\u4e86\u514d\u75ab\u7597\u6cd5\u4e3a\u65e9\u671f\u8180\u80f1\u764c\u6cbb\u7597\u5e26\u6765\u7684\u76ca\u5904\uff0c\u8fdb\u800c\u9610\u91ca\u6211\u4eec\u7684\u7b56\u7565\u2014\u2014\u5c06\u524d\u6cbf\u6cbb\u7597\u5f15\u5165\u764c\u75c7\u65e9\u671f\u8fd9\u4e00\u60a3\u8005\u6700\u80fd\u591f\u83b7\u76ca\u7684\u9636\u6bb5\u3002&#8221;<\/p>\n<p>\u5176\u4ed6\u4eae\u70b9\u5305\u62ec\uff1a<\/p>\n<p>                    FONTANA\uff1a\u8bc4\u4f30\u9776\u5411\u53f6\u9178\u53d7\u4f53\u03b1\uff08FR\u03b1\uff09\u7684\u6297\u4f53\u836f\u7269\u5076\u8054\u7269AZD5335\u7528\u4e8e\u94c2\u8010\u836f\u590d\u53d1\u6027\u5375\u5de2\u764c\u60a3\u8005\u7684I\/IIa\u671f\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u8bd5\u9a8c\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#1065MO\uff09\u3002<\/p>\n<p>                    PETRANHA\uff1a\u8bc4\u4f30saruparib\u8054\u5408\u96c4\u6fc0\u7d20\u53d7\u4f53\u901a\u8def\u6291\u5236\u5242\u7528\u4e8e\u6cbb\u7597\u8f6c\u79fb\u6027\u524d\u5217\u817a\u764c\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#2384MO\uff09\u3002<\/p>\n<p>                    ARTEMIDE<br \/>\n                    -01\uff1a\u8bc4\u4f30rilvegostomig\u7528\u4e8e\u68c0\u67e5\u70b9\u6291\u5236\u5242\u521d\u6cbb\u7684\u8f6c\u79fb\u6027\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#1853MO\uff09\u3002<\/p>\n<p>                    FLAURA2\uff1a\u5728\u5965\u5e0c\u66ff\u5c3c\u5408\u5316\u7597\u6cbb\u7597\u665a\u671fEGFR\u7a81\u53d8NSCLC\u60a3\u8005\u7684FLAURA2 III\u671f\u4e34\u5e8a\u7814\u7a76\u4e2d\u5b58\u5728\u4e0d\u826f\u9884\u540e\u56e0\u7d20\u60a3\u8005\u7684\u63a2\u7d22\u6027OS\u5206\u6790\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA77\uff09\u3002<\/p>\n<p>                    CAPItello<br \/>\n                    -281\uff1a\u5361\u5339\u8272\u66ff\u8054\u5408\u963f\u6bd4\u7279\u9f99\u548c\u96c4\u6fc0\u7d20\u5265\u593a\u7597\u6cd5\uff08ADT\uff09\u7528\u4e8ePTEN\u7f3a\u9677\u7684\u65b0\u53d1\u8f6c\u79fb\u6027\u6fc0\u7d20\u654f\u611f\u6027\u524d\u5217\u817a\u764c\uff08mHSPC\uff09\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#2383O\uff09\u3002<\/p>\n<p>                    TROPION<br \/>\n                    -PanTumor03\uff1a\u8bc4\u4f30\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u8054\u5408rilvegostomig\u6cbb\u7597\u5c40\u665a\u671f\u6216\u8f6c\u79fb\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\uff08a\/mUC\uff09\u60a3\u8005\u7684\u7597\u6548\uff1a II\u671fTROPION-PanTumor03\u7814\u7a76\u7ed3\u679c\u7ed3\u679c\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981 #3072MO\uff09<\/p>\n<p>                    BEGONIA<br \/>\n                    \uff1a\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u8054\u5408\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u7528\u4e8e\u65e2\u5f80\u672a\u7ecf\u6cbb\u7597\u7684\u4e0d\u53ef\u5207\u9664\u3001\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u60a3\u8005\u7684BEGONIA Ib\/II\u671f\u8bd5\u9a8c\u6700\u7ec8\u7ed3\u679c\uff08\u53e3\u5934\u62a5\u544a\u6458\u8981#555MO\uff09\u3002<\/p>\n<p>\u963f\u65af\u5229\u5eb7\u4e0e\u7b2c\u2f00\u4e09\u5171\u8054\u5408\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u4e0e\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\uff1b\u4e0e\u9ed8\u6c99\u4e1c\uff08\u9ed8\u6c99\u4e1c\u662f\u7f8e\u56fd\u65b0\u6cfd\u897f\u5dde\u7f57\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u516c\u53f8\u5546\u53f7\uff09\u8054\u5408\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u5965\u62c9\u5e15\u5229\uff1b\u4e0e\u548c\u9ec4\u533b\u836f\u5408\u4f5c\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u8d5b\u6c83\u66ff\u5c3c\u3002Rilvegostomig\u662f\u4e00\u79cd\u9776\u5411PD-1\u548cTIGIT\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff0c\u5176\u4e2dTIGIT\u90e8\u5206\u6e90\u81eaCompugen\u516c\u53f8\u4e34\u5e8a\u9636\u6bb5\u7684\u6297TIGIT\u6297\u4f53COM902\u3002<\/p>\n<p>\n                  \u963f\u65af\u5229\u5eb7\u57282025\u5e74ESMO\u5e74\u4f1a\u671f\u95f4\u7684\u91cd\u8981\u6f14\u8bb2[1]\n                <\/p>\n<div>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            \u4e3b\u8981\u4f5c\u8005<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            \u6458\u8981\u6807\u9898<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            \u62a5\u544a\u8be6\u60c5(CEST)<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            \u6297\u4f53\u5076\u8054\u836f\u7269<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Harbeck, N<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan <br \/>alone (T-DXd) or followed by paclitaxel + trastuzumab +<br \/>pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ <br \/>early breast cancer (eBC)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #291O<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Presidential 1<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">18 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">4:30 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Geyer, C<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Trastuzumab deruxtecan (T-DXd) vs trastuzumab <br \/>emtansine (T-DM1) in patients (pts) with high-risk human <br \/>epidermal growth factor receptor 2\u2013positive (HER2+) <br \/>primary breast cancer (BC) with residual invasive disease <br \/>after neoadjuvant therapy (tx): Interim analysis of <br \/>DESTINY-Breast05<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA1<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Presidential 1<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">18 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">4:52 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Dent, R.<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">First-line (1L) datopotamab deruxtecan (Dato-DXd) vs <br \/>chemotherapy in patients with locally recurrent inoperable <br \/>or metastatic triple-negative breast cancer (mTNBC) for <br \/>whom immunotherapy was not an option: Primary results <br \/>from the randomised, phase 3 TROPION-Breast02 trial<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA21<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">19 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">9:25 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Loibl, S<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane <br \/>+ trastuzumab + pertuzumab (THP) for patients with <br \/>HER2+ advanced\/metastatic breast cancer: additional <br \/>analysis of DESTINY-Breast09 in key subgroups of interest<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA18<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">19 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">8:30 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Rha, SY<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Datopotamab deruxtecan (Dato-DXd) + rilvegostomig <br \/>(rilve) in patients (pts) with locally advanced or metastatic <br \/>urothelial cancer (a\/mUC): Results from the phase 2 <br \/>TROPION-PanTumor03 study<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #3072MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">17 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">4:10 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Oaknin, A<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">First-in-human study of AZD5335, a folate receptor \u03b1<br \/>(FR\u03b1)-targeted antibody-drug conjugate, in patients with <br \/>platinum-resistant recurrent ovarian cancer<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1065MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">19 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">10:53 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Schmid, P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as <br \/>first-line (1L) treatment (tx) for unresectable locally <br \/>advanced\/metastatic triple-negative breast cancer <br \/>(a\/mTNBC): Final results from the phase 1b\/2 BEGONIA <br \/>study<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #555MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">20 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">10:50 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Raghav, K<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Trastuzumab deruxtecan (T DXd) in patients (pts) with <br \/>HER2-positive (HER2+) metastatic colorectal cancer<br \/>(mCRC): Final analysis of DESTINY-CRC02, a <br \/>randomized, phase 2 trial<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #737P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Peng, Z<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Trastuzumab deruxtecan (T-DXd) in patients (pts) with <br \/>HER2+ gastric cancer (GC) or gastroesophageal junction <br \/>adenocarcinoma (GEJA) who received prior anti-HER2 <br \/>treatment (Tx) other than \/ in addition to trastuzumab in <br \/>DESTINY-Gastric06 (DG-06)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #2105P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Shen, L<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Risk of hepatitis B virus reactivation (HBVr) in patients<br \/>(pts) with past or resolved HBV or inactive chronic HBV<br \/>infection treated with trastuzumab deruxtecan (T-DXd) in <br \/>the DESTINY-Gastric06 (DG-06) trial<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #2175P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Pietrantonio, F<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) <br \/>plus paclitaxel (PTX) in second-line (2L) treatment of <br \/>patients (pts) with HER2+ unresectable\/metastatic gastric <br \/>cancer (GC)\/gastroesophageal junction adenocarcinoma<br \/>(GEJA): Additional data from DESTINY-Gastric04 (DG-04)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #2099P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Makker, V<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Trastuzumab deruxtecan (T-DXd) for pretreated patients <br \/>(pts) with HER2-expressing solid tumors: DESTINY-<br \/>PanTumor02 (DP-02) Part 1 final analysis<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #957P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Lee, J-Y<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Trastuzumab deruxtecan (T-DXd) in pretreated patients <br \/>(pts) with HER2-expressing solid tumors: exploratory <br \/>biomarker analysis of DESTINY-PanTumor02 (DP-02) Part <br \/>1<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #145P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            \u514d\u75ab\u80bf\u7624\u5b66<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Tabernero, J<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">MATTERHORN Phase III trial of Imfinzi (durvalumab) <br \/>perioperative Imfinzi (durvalumab) plus FLOT <br \/>chemotherapy in patients with resectable, early-stage and <br \/>locally advanced gastric and gastroesophageal junction<br \/>(GEJ) cancers<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA81<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">17 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">2:00 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">De Santis, M<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Durvalumab (D) in Combination with Bacillus Calmette-<br \/>Gu\u00e9rin (BCG) for BCG-na\u00efve, High-risk Non-muscle-<br \/>invasive Bladder Cancer (NMIBC): Results from the Phase<br \/>3, Open-label, Randomised POTOMAC Trial<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA108<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">17 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">2:10 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Larkin, J<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">First results from RAMPART: An international phase 3<br \/>randomised-controlled trial of adjuvant durvalumab<br \/>monotherapy or combined with tremelimumab for resected<br \/>primary renal cell carcinoma (RCC) led by MRC CTU at <br \/>UCL<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA93<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">18 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">9:20 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Aghajanian, C<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Durvalumab + paclitaxel\/carboplatin + bevacizumab<br \/>followed by durvalumab, bevacizumab + olaparib <br \/>maintenance in patients with newly diagnosed non-tBRCA-<br \/>mutated advanced ovarian cancer: final overall survival <br \/>from DUO-O\/ENGOT-ov46\/GOG-3025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA44<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">19 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">11:31 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Goss, G<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">CCTG BR.31: Adjuvant durvalumab (D) in resected non-<br \/>small-cell lung cancer (NSCLC): final overall survival (OS) <br \/>and minimal residual disease (MRD) analyses<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA68<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">20 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">3:20 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Heymach, J<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Association of radiomic features \u00b1 on-treatment ctDNA <br \/>detection with treatment outcomes in patients with <br \/>resectable NSCLC: exploratory analyses from AEGEAN<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA70<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">20 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">3:50 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Wermke, M<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Tarlatamab with first-line chemoimmunotherapy for <br \/>extensive stage small cell lung cancer (ES-SCLC):<br \/>DeLLphi-303 study<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #2757O<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">18 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">8:30 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Loibl, S<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Durvalumab in Combination with Neoadjuvant <br \/>Chemotherapy in Early Triple-Negative Breast Cancer <br \/>(TNBC) \u2013 Long-term Analysis from the GeparNuevo Trial<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #292MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">19 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">10:15 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Van der Heijden, M<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Health-related quality of life (HRQoL) from the NIAGARA <br \/>trial of perioperative durvalumab (D) plus neoadjuvant <br \/>chemotherapy (NAC) in muscle-invasive bladder cancer<br \/>(MIBC)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #3069MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">17 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">4:00 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Sangro, B<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Pooled efficacy and safety outcomes with tremelimumab <br \/>plus durvalumab in participants (pts) with unresectable <br \/>hepatocellular carcinoma (uHCC) from the combined <br \/>China extension and global cohorts in the Phase 3 <br \/>HIMALAYA study<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1494P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Westin, S<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Durvalumab plus carboplatin\/paclitaxel followed by <br \/>durvalumab for endometrial cancer: Tumour mutational <br \/>burden-high subpopulation efficacy analyses from the <br \/>DUO-E trial<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1117P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Leal, TA<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Global quantitative assessment of multidisciplinary team<br \/>(MDT) care in early-stage NSCLC<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1794P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Reck, M<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Neoadjuvant durvalumab (D) + chemotherapy (CT) <br \/>followed by either surgery (Sx) and adjuvant D or CRT and <br \/>consolidation D in patients (pts) with resectable or <br \/>borderline resectable stage IIB\u2013IIIB NSCLC: interim <br \/>analysis (IA) of the phase 2 MDT-BRIDGE study<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA65<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">18 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">9:15 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Maruki, Y<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">CELEBRATE Study (JCOG2107E): A Multicenter, Open-<br \/>label, Phase III Trial of Etoposide, Carboplatin, and <br \/>Durvalumab in First-line Treatment of Unresectable or <br \/>Recurrent Digestive NEC<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1734TiP<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Oudard, S<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">A phase IIIb, open-label, single-arm, global study of <br \/>perioperative durvalumab (D) with neoadjuvant dose-<br \/>dense methotrexate, vinblastine, doxorubicin, and cisplatin<br \/>(ddMVAC) or gemcitabine\/cisplatin (gem\/cis) in patients <br \/>with muscle-invasive bladder cancer (MIBC) (NIAGARA-2)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #3133eTiP<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">ePoster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            \u53cc\u7279\u5f02\u6027\u6297\u4f53<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Chul Cho, B<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Efficacy and Safety of Rilvegostomig, an Anti-PD-1\/TIGIT<br \/>Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Na\u00efve <br \/>Metastatic Non-Small-Cell Lung Cancer (mNSCLC): <br \/>ARTEMIDE-01<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1853MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">20 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">10:25 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Slomovitz, BM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">A randomized Phase 3 study of first-line (1L) trastuzumab <br \/>deruxtecan (T-DXd) with rilvegostomig or pembrolizumab <br \/>in patients with HER2-expressing, mismatch repair-<br \/>proficient (pMMR), primary advanced or recurrent <br \/>endometrial cancer (EC): DESTINY-Endometrial01\/GOG-<br \/>3098\/ENGOT-EN24<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1223TiP<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Naidoo, J<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">ARTEMIDE-Lung04: A Phase 3, randomised, double-blind, <br \/>global study of rilvegostomig or pembrolizumab <br \/>monotherapy as first-line (1L) treatment for patients with <br \/>metastatic non-small cell lung cancer (mNSCLC) and <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">programmed cell death ligand-1 (PD-L1) expression \u226550%<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #2025TiP<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            \u80bf\u7624\u9a71\u52a8\u56e0\u5b50\u548c\u8010\u836f\u6027<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">J\u00e4nne, PA<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">FLAURA2: exploratory overall survival (OS) analysis in<br \/>patients (pts) with poor prognostic factors treated with <br \/>osimertinib (osi) \u00b1 platinum-pemetrexed chemotherapy<br \/>(CTx) as first-line (1L) treatment for EGFR-mutated <br \/>(EGFRm) advanced NSCLC<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #LBA77<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">17 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">4:56 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mayer, E<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Patient-reported outcomes (PROs) from the SERENA-6 <br \/>trial of camizestrant (CAMI) + CDK4\/6 inhibitor (CDK4\/6i) <br \/>for emergent ESR1m during first-line (1L) endocrine-based<br \/>therapy and ahead of disease progression in patients (pts) <br \/>with HR+\/HER2- advanced breast cancer (ABC)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #486MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">20 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">10:25 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Arriola, E<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Molecular residual disease (MRD) analysis from the <br \/>LAURA study of osimertinib (osi) in unresectable (UR)<br \/>stage III EGFR-mutated (EGFRm) NSCLC<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1817MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">20 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">2:55 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Park, YH<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Visual symptom questionnaire results from SERENA-6, a <br \/>Phase 3 study of switch to camizestrant (CAMI) + CDK4\/6<br \/>inhibitor (CDK4\/6i) at emergence of ESR1m during first-<br \/>line (1L) therapy for patients (pts) with HR+\/HER2- <br \/>advanced breast cancer (ABC)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #528P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Chu, Q<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">SAVANNAH: Safety and tolerability of osimertinib (osi) + <br \/>savolitinib (savo) in EGFRm advanced NSCLC with MET <br \/>overexpression and\/or amplification (OverExp\/Amp) <br \/>following disease progression on osi<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1955P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Rotow, J<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">MET testing and treatment (tx) sequencing after <br \/>progression on first line (1L) osimertinib (osi) in patients <br \/>(pts) with EGFRm advanced NSCLC and acquired MET<br \/>overexpression and\/or amplification (OverExp\/Amp): <br \/>Interim analysis of a global real world (rw) study<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1967P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Yu, Y<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo) <br \/>plus osimertinib (osi) versus chemotherapy (chemo) in <br \/>MET-amplified (METamp) advanced NSCLC after disease <br \/>progression (PD) on EGFR tyrosine kinase inhibitor (TKI)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1954P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            DNA\u635f\u4f24\u5e94\u7b54<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Azad, AA<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">First interim efficacy analysis of the Phase 1\/2 PETRANHA <br \/>trial of saruparib + androgen receptor pathway inhibitors <br \/>(ARPI) in patients (pts) with metastatic prostate cancer<br \/>(mPC)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #2384MO<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Mini Oral Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">17 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">2:35 PM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Fizazi, K<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">A Phase 3 study of capivasertib (capi) + abiraterone (abi) <br \/>vs placebo (pbo) + abi in patients (pts) with PTEN deficient <br \/>de novo metastatic hormone-sensitive prostate cancer<br \/>(mHSPC): CAPItello-281<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #2383O<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Proffered Paper Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">19 October 2025<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">11:19 AM<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Rugo, HS<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Capivasertib with fulvestrant as first- and second-line<br \/>endocrine therapy in PIK3CA\/AKT1\/PTEN-altered <br \/>hormone receptor-positive advanced breast cancer: <br \/>Subgroup analysis from the Phase 3 CAPItello-291 trial<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #526P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Gao, Q<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Final overall survival (OS) analysis of L-MOCA: olaparib <br \/>maintenance monotherapy in patients (pts) with platinum-<br \/>sensitive relapsed ovarian cancer (PSR OC)<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #1090P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\"><br \/>\n                            AI<br \/>\n                            \u9a71\u52a8\u7684\u4e34\u5e8a\u8bd5\u9a8c<br \/>\n                          <\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Gonuguntla, HK<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Real-World Validation of AI-defined Lung Nodule<br \/>Malignancy Score (qXR-LNMS) in Predicting Risk of Lung <br \/>Cancer: Interim results from Phase 2<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Abstract #2978P<\/span>\n                        <\/p>\n<p class=\"prnml4\">\n                          <span class=\"prnews_span\">Poster Session<\/span>\n                        <\/p>\n<\/div>\n<p>\n                  [1]\u963f\u65af\u5229\u5eb7\u57282025\u5e74ESMO\u5e74\u4f1a\u5c06\u516c\u5e03\u903e90\u4e2a\u6458\u8981\uff0c\u6db5\u76d6\u5176\u4ea7\u54c1\u548c\u7ba1\u7ebf\u4e2d\u7684\u5206\u5b50\u836f\u7269<\/p>\n<p>                    \u5173\u4e8e\u963f\u65af\u5229\u5eb7\u80bf\u7624\u9886\u57df\u7684\u7814\u7a76 <\/p>\n<p>\u963f\u65af\u5229\u5eb7\u6b63\u5f15\u9886\u7740\u80bf\u7624\u9886\u57df\u7684\u2f00\u573a\u9769\u547d\uff0c\u81f4\u529b\u63d0\u4f9b\u591a\u5143\u5316\u7684\u80bf\u7624\u6cbb\u7597\u65b9\u6848\uff0c\u4ee5\u79d1\u5b66\u63a2\u7d22\u80bf\u7624\u9886\u57df\u7684\u590d\u6742\u6027\uff0c\u53d1\u73b0\u3001\u7814\u53d1\u5e76\u5411\u60a3\u8005\u63d0\u4f9b\u6539\u53d8\u751f\u547d\u7684\u836f\u7269\u3002<\/p>\n<p>\u963f\u65af\u5229\u5eb7\u4e13\u6ce8\u4e8e\u6700\u5177\u6311\u6218\u6027\u7684\u80bf\u7624\u75be\u75c5\uff0c\u901a\u8fc7\u6301\u7eed\u4e0d\u65ad\u7684\u521b\u65b0\uff0c\u963f\u65af\u5229\u5eb7\u5df2\u7ecf\u5efa\u7acb\u4e86\u884c\u4e1a\u9886\u5148\u7684\u591a\u5143\u5316\u7684 \u4ea7\u54c1\u7ec4\u5408\u548c\u7ba1\u7ebf\uff0c\u6301\u7eed\u63a8\u52a8\u533b\u7597\u5b9e\u8df5\u53d8\u2fb0\uff0c\u6539\u53d8\u60a3\u8005\u4f53\u9a8c\u3002<\/p>\n<p>\u963f\u65af\u5229\u5eb7\u4ee5\u671f\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u5e76\u5728\u672a\u6765\u653b\u514b\u764c\u75c7\u3002<\/p>\n<p>                    \u5173\u4e8e\u963f\u65af\u5229\u5eb7 <\/p>\n<p>\u963f\u65af\u5229\u5eb7\uff08LSE\/STO\/Nasdaq: AZN\uff09\u662f\u2f00\u5bb6\u79d1\u5b66\u81f3\u4e0a\u7684\u5168\u7403\u751f\u7269\u5236\u836f\u4f01\u4e1a\uff0c\u4e13\u6ce8\u4e8e\u7814\u53d1\u3001\u751f\u4ea7\u53ca\u8425\u9500\u5904\u65b9\u7c7b\u836f\u54c1\uff0c\u91cd\u70b9\u5173\u6ce8\u80bf\u7624\u3001\u7f55\u89c1\u75c5\u4ee5\u53ca\u5305\u62ec\u5fc3\u8840\u7ba1\u80be\u810f\u53ca\u4ee3\u8c22\u3001\u547c\u5438\u53ca\u514d\u75ab\u5728\u5185\u7684\u751f\u7269\u5236\u836f\u7b49\u9886\u57df\u3002\u963f\u65af\u5229\u5eb7\u5168\u7403\u603b\u90e8\u4f4d\u4e8e\u82f1\u56fd\u5251\u6865\uff0c\u4e1a\u52a1\u904d\u5e03\u8d85\u8fc7125\u4e2a\u56fd\u5bb6\uff0c\u521b\u65b0\u836f\u7269\u60e0\u53ca\u5168\u7403\u6570\u767e\u4e07\u60a3\u8005\u3002\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee<a href=\"http:\/\/www.astrazeneca.com\/\" target=\"_blank\" rel=\"noopener\">www.astrazeneca.com<\/a>\u3002<\/p>\n<p>                    \u5173\u4e8e\u963f\u65af\u5229\u5eb7\u4e2d\u56fd <\/p>\n<p>\u963f\u65af\u5229\u5eb7\u81ea1993\u5e74\u8fdb\u5165\u4e2d\u56fd\u4ee5\u6765\uff0c\u4e13\u6ce8\u4e2d\u56fd\u60a3\u8005\u9700\u6c42\u6700\u8feb\u5207\u7684\u6cbb\u7597\u9886\u57df\uff0c\u5305\u62ec\u80bf\u7624\u3001\u5fc3\u8840\u7ba1\u3001\u80be\u810f\u3001\u4ee3\u8c22\u3001\u547c\u5438\u3001\u6d88\u5316\u3001\u7f55\u89c1\u75c5\u3001\u75ab\u82d7\u6297\u4f53\u53ca\u81ea\u4f53\u514d\u75ab\u7b49\uff0c\u5df2\u5c0640\u591a\u6b3e\u521b\u65b0\u836f\u7269\u5e26\u5230\u4e2d\u56fd\u3002\u963f\u65af\u5229\u5eb7\u4e2d\u56fd\u603b\u90e8\u4f4d\u4e8e\u4e0a\u6d77\uff0c\u5e76\u5728\u4e0a\u6d77\u548c\u5317\u4eac\u8bbe\u7acb\u5168\u7403\u6218\u7565\u7814\u53d1\u4e2d\u5fc3\uff0c\u5728\u5317\u4eac\u3001\u5e7f\u5dde\u3001\u676d\u5dde\u3001\u6210\u90fd\u3001\u9752\u5c9b\u8bbe\u7acb\u533a\u57df\u603b\u90e8\uff0c\u5728\u65e0\u9521\u3001\u6cf0\u5dde\u3001\u9752\u5c9b\u5efa\u7acb\u5168\u7403\u751f\u4ea7\u4f9b\u5e94\u57fa\u5730\uff0c\u5411\u5168\u740370\u591a\u4e2a\u5e02\u573a\u8f93\u9001\u4f18\u8d28\u521b\u65b0\u836f\u54c1\u3002<\/p>\n<p>                    \u58f0\u660e\uff1a\u672c\u6587\u7814\u7a76\u4e2d\u6d89\u53ca\u7684\u591a\u79cd\u836f\u54c1\u7528\u6cd5\u5c1a\u672a\u5728\u4e2d\u56fd\u83b7\u6279\u9002\u5e94\u75c7\uff0c\u963f\u65af\u5229\u5eb7\u4e0d\u63a8\u8350\u4efb\u4f55\u672a\u88ab\u6279\u51c6\u7684\u836f\u54c1\u4f7f\u7528\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\"><\/div>\n<p>SOURCE \u963f\u65af\u5229\u5eb7<\/p>","protected":false},"excerpt":{"rendered":"<p>DESTINY-Breast11\u4e0eDESTINY-Breast05\u4e24\u9879\u7814\u7a76\u5165\u9009\u4e3b\u5e2d\u7814\u8ba8\u4f1a\uff08Presidential Symposium\uff09\uff0c\u51f8\u663e\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u5728\u6cbb\u7597HER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\u4e2d\u7684\u6f5c\u5728\u4ef7\u503c TROPION-Breast02\u7814\u7a76\u6570\u636e\u5c06\u5c55\u793a\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u5728\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\u8fd9\u4e00\u6700\u5177\u4fb5\u88ad\u6027\u7684\u4e73\u817a\u764c\u5206\u578b\u4e2d\u7684\u6cbb\u7597\u6f5c\u529b POTOMAC\u7814\u7a76\u7684\u65e0\u75c5\u751f\u5b58\u671f\u6570\u636e\u4e0eMATTERHORN\u7814\u7a76\u7684\u751f\u5b58\u671f\u6570\u636e\u5c06\u5c55\u793a\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u5728\u65e9\u671f\u8180\u80f1\u764c\u4e0e\u80c3\u764c\u6cbb\u7597\u4e2d\u7684\u83b7\u76ca \u4e0a\u6d77 2025\u5e7410\u670814\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;\u00a0\u963f\u65af\u5229\u5eb7\u5c06\u4e8e2025\u5e7410\u670817\u65e5\u81f321\u65e5\u53ec\u5f00\u7684\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\u4e0a\uff0c\u51ed\u501f\u2f8f\u4e1a\u9886\u5148\u7684\u591a\u6837\u5316\u4ea7\u54c1\u4e0e\u7ba1\u7ebf\u5e03\u5c40\u7684\u5168\u65b0\u7814\u7a76\u6570\u636e\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u5176\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u683c\u5c40\u7684\u96c4\u5fc3\u58ee\u5fd7\u3002 \u672c\u6b21\u5927\u4f1a\u4e0a\uff0c\u963f\u65af\u5229\u5eb7\u5c06\u516c\u5e03\u903e95\u9879\u6458\u8981\uff0c\u6db5\u76d69\u6b3e\u5df2\u83b7\u5f97\u6279\u51c6\u836f\u7269\u53ca9\u6b3e\u6f5c\u5728\u65b0\u836f\uff0c\u5305\u62ec2\u9879\u5165\u9009\u91cd\u8981\u4e3b\u5e2d\u7814\u8ba8\u4f1a\uff08Presidential Symposium\uff09\u7684\u6458\u8981\u4ee5\u53ca26\u9879\u53e3\u5934\u62a5\u544a\u3002 \u5176\u4e2d\u4e3b\u8981\u4eae\u70b9\u5305\u62ec\uff1a DESTINY-Breast11\uff1a\u8bc4\u4f30\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u5e8f\u8d2fTHP\u65b9\u6848\uff08\u7d2b\u6749\u9187\u3001\u66f2\u59a5\u73e0\u5355\u6297\u53ca\u5e15\u59a5\u73e0\u5355\u6297\uff09\u7528\u4e8e\u9ad8\u98ce\u9669HER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\u65b0\u8f85\u52a9\u6cbb\u7597\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4e3b\u5e2d\u7814\u8ba8\u4f1a1\uff0c\u6458\u8981#291O\uff09\u3002 DESTINY-Breast05\uff1a\u8bc4\u4f30\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u7528\u4e8eHER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\uff08\u65b0\u8f85\u52a9\u6cbb\u7597\u540e\u5b58\u5728\u6b8b\u7559\u6d78\u6da6\u75c5\u7076\u5e76\u5177\u6709\u9ad8\u590d\u53d1\u98ce\u9669\uff09\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4e3b\u5e2d\u7814\u8ba8\u4f1a1\uff0c\u6458\u8981#LBA1\uff09\u3002\u00a0 TROPION-Breast02\uff1a\u8bc4\u4f30\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u7528\u4e8e\u4e00\u7ebf\u6cbb\u7597\u65e0\u6cd5\u63a5\u53d7\u514d\u75ab\u6cbb\u7597\u7684\u5c40\u90e8\u590d\u53d1\u6027\u4e0d\u53ef\u624b\u672f\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA21\uff09\u3002 POTOMAC \uff1a\u8bc4\u4f30\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408\u5361\u4ecb\u82d7\uff08BCG\uff09\u8bf1\u5bfc\u4e0e\u7ef4\u6301\u6cbb\u7597\uff0c\u7528\u4e8e\u9ad8\u5371\u975e\u808c\u5c42\u6d78\u6da6\u6027\u8180\u80f1\u764c\uff08NMIBC\uff09\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA108\uff09\u3002 MATTERHORN\uff1a\u516c\u5e03III\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u6700\u7ec8\u603b\u751f\u5b58\u671f\uff08OS\uff09\u7ed3\u679c\uff0c\u8bc4\u4f30\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408FLOT\u5316\u7597\u4f5c\u4e3a\u53ef\u5207\u9664\u7684\u65e9\u671f\u548c\u5c40\u90e8\u665a\u671f\u7684\u80c3\u548c\u80c3\u2edd\u7ba1\u7ed3\u5408\u90e8\u817a\u764c\uff08GEJ\uff09\u60a3\u8005\u56f4\u624b\u672f\u671f\u6cbb\u7597\u4e2d\u7684\u4e34\u5e8a\u83b7\u76ca\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA81\uff09\u3002 \u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\u3001\u5168\u7403\u80bf\u7624\u7814\u53d1\u8d1f\u8d23\u4eba\u9ad8\u4e66\u74a8\uff08Susan Galbraith\uff09\u8868\u793a\uff1a&#8221;\u6211\u4eec\u6b63\u52a0\u901f\u63a8\u8fdb\u591a\u5143\u521b\u65b0\u7597\u6cd5\u7ba1\u7ebf\uff0c\u4ee5\u53d8\u9769\u4e73\u817a\u764c\u60a3\u8005\u7684\u6cbb\u7597\u683c\u5c40\u3002\u5728\u672c\u5c4aESMO\u5927\u4f1a\u4e0a\uff0c\u6211\u4eec\u5c06\u516c\u5e03TROPION-Breast02\u3001DESTINY-Breast11\u548cDESTINY-Breast05\u7814\u7a76\u7684\u6570\u636e\u548c\u91cd\u8981\u8fdb\u5c55\u3002\u540c\u65f6\uff0c\u6211\u4eec\u4e5f\u5c06\u5c55\u793a\u65b0\u4e00\u4ee3\u6f5c\u5728\u6297\u80bf\u7624\u65b0\u836f\u7684\u6570\u636e\uff0c\u5305\u62ecsaruparib\u8054\u5408\u65b0\u578b\u6fc0\u7d20\u7597\u6cd5\u7528\u4e8e\u524d\u5217\u817a\u764c\u9886\u57df\uff0c\u9776\u5411\u53f6\u9178\u53d7\u4f53\u7684\u6297\u4f53\u5076\u8054\u836f\u7269torvu-sam\u7528\u4e8e\u5375\u5de2\u764c\u9886\u57df\uff0c\u4ee5\u53carilvegostomig\u7528\u4e8e\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u9886\u57df\u3002&#8221; \u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\uff0c\u80bf\u7624\u4e1a\u52a1\u8d1f\u8d23\u4ebaDave Fredrickson\u8868\u793a\uff1a&#8221;\u6211\u4eec\u4e1a\u754c\u9886\u5148\u7684\u80bf\u7624\u4ea7\u54c1\u7ec4\u5408\u5728\u672c\u6b21ESMO\u6301\u7eed\u5c55\u73b0\u5f3a\u52b2\u52bf\u5934\uff0c\u9996\u6b21\u516c\u5e03\u4e86\u56db\u9879\u5173\u952e\u7814\u7a76\u7684\u6570\u636e\u3002\u5176\u4e2d\uff0c\u4e0d\u4ec5\u6709\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u548c\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u5728\u4e73\u817a\u764c\u9886\u57df\u7684\u91cd\u5927\u8fdb\u5c55\uff0c\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u7684POTOMAC\u8bd5\u9a8c\u7ed3\u679c\u4e5f\u8bc1\u660e\u4e86\u514d\u75ab\u7597\u6cd5\u4e3a\u65e9\u671f\u8180\u80f1\u764c\u6cbb\u7597\u5e26\u6765\u7684\u76ca\u5904\uff0c\u8fdb\u800c\u9610\u91ca\u6211\u4eec\u7684\u7b56\u7565\u2014\u2014\u5c06\u524d\u6cbf\u6cbb\u7597\u5f15\u5165\u764c\u75c7\u65e9\u671f\u8fd9\u4e00\u60a3\u8005\u6700\u80fd\u591f\u83b7\u76ca\u7684\u9636\u6bb5\u3002&#8221; \u5176\u4ed6\u4eae\u70b9\u5305\u62ec\uff1a FONTANA\uff1a\u8bc4\u4f30\u9776\u5411\u53f6\u9178\u53d7\u4f53\u03b1\uff08FR\u03b1\uff09\u7684\u6297\u4f53\u836f\u7269\u5076\u8054\u7269AZD5335\u7528\u4e8e\u94c2\u8010\u836f\u590d\u53d1\u6027\u5375\u5de2\u764c\u60a3\u8005\u7684I\/IIa\u671f\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u8bd5\u9a8c\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#1065MO\uff09\u3002 PETRANHA\uff1a\u8bc4\u4f30saruparib\u8054\u5408\u96c4\u6fc0\u7d20\u53d7\u4f53\u901a\u8def\u6291\u5236\u5242\u7528\u4e8e\u6cbb\u7597\u8f6c\u79fb\u6027\u524d\u5217\u817a\u764c\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#2384MO\uff09\u3002 ARTEMIDE -01\uff1a\u8bc4\u4f30rilvegostomig\u7528\u4e8e\u68c0\u67e5\u70b9\u6291\u5236\u5242\u521d\u6cbb\u7684\u8f6c\u79fb\u6027\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#1853MO\uff09\u3002 FLAURA2\uff1a\u5728\u5965\u5e0c\u66ff\u5c3c\u5408\u5316\u7597\u6cbb\u7597\u665a\u671fEGFR\u7a81\u53d8NSCLC\u60a3\u8005\u7684FLAURA2 III\u671f\u4e34\u5e8a\u7814\u7a76\u4e2d\u5b58\u5728\u4e0d\u826f\u9884\u540e\u56e0\u7d20\u60a3\u8005\u7684\u63a2\u7d22\u6027OS\u5206\u6790\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA77\uff09\u3002 CAPItello -281\uff1a\u5361\u5339\u8272\u66ff\u8054\u5408\u963f\u6bd4\u7279\u9f99\u548c\u96c4\u6fc0\u7d20\u5265\u593a\u7597\u6cd5\uff08ADT\uff09\u7528\u4e8ePTEN\u7f3a\u9677\u7684\u65b0\u53d1\u8f6c\u79fb\u6027\u6fc0\u7d20\u654f\u611f\u6027\u524d\u5217\u817a\u764c\uff08mHSPC\uff09\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#2383O\uff09\u3002 TROPION -PanTumor03\uff1a\u8bc4\u4f30\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u8054\u5408rilvegostomig\u6cbb\u7597\u5c40\u665a\u671f\u6216\u8f6c\u79fb\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\uff08a\/mUC\uff09\u60a3\u8005\u7684\u7597\u6548\uff1a II\u671fTROPION-PanTumor03\u7814\u7a76\u7ed3\u679c\u7ed3\u679c\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981 #3072MO\uff09 BEGONIA \uff1a\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u8054\u5408\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u7528\u4e8e\u65e2\u5f80\u672a\u7ecf\u6cbb\u7597\u7684\u4e0d\u53ef\u5207\u9664\u3001\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u60a3\u8005\u7684BEGONIA Ib\/II\u671f\u8bd5\u9a8c\u6700\u7ec8\u7ed3\u679c\uff08\u53e3\u5934\u62a5\u544a\u6458\u8981#555MO\uff09\u3002 \u963f\u65af\u5229\u5eb7\u4e0e\u7b2c\u2f00\u4e09\u5171\u8054\u5408\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u4e0e\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\uff1b\u4e0e\u9ed8\u6c99\u4e1c\uff08\u9ed8\u6c99\u4e1c\u662f\u7f8e\u56fd\u65b0\u6cfd\u897f\u5dde\u7f57\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u516c\u53f8\u5546\u53f7\uff09\u8054\u5408\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u5965\u62c9\u5e15\u5229\uff1b\u4e0e\u548c\u9ec4\u533b\u836f\u5408\u4f5c\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u8d5b\u6c83\u66ff\u5c3c\u3002Rilvegostomig\u662f\u4e00\u79cd\u9776\u5411PD-1\u548cTIGIT\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff0c\u5176\u4e2dTIGIT\u90e8\u5206\u6e90\u81eaCompugen\u516c\u53f8\u4e34\u5e8a\u9636\u6bb5\u7684\u6297TIGIT\u6297\u4f53COM902\u3002 \u963f\u65af\u5229\u5eb7\u57282025\u5e74ESMO\u5e74\u4f1a\u671f\u95f4\u7684\u91cd\u8981\u6f14\u8bb2[1] \u4e3b\u8981\u4f5c\u8005 \u6458\u8981\u6807\u9898 \u62a5\u544a\u8be6\u60c5(CEST) \u6297\u4f53\u5076\u8054\u836f\u7269 Harbeck, N DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":16865,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-16864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3 - Money Compass CN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/moneycompass.com.my\/cn\/\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3 - Money Compass CN\" \/>\n<meta property=\"og:description\" content=\"DESTINY-Breast11\u4e0eDESTINY-Breast05\u4e24\u9879\u7814\u7a76\u5165\u9009\u4e3b\u5e2d\u7814\u8ba8\u4f1a\uff08Presidential Symposium\uff09\uff0c\u51f8\u663e\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u5728\u6cbb\u7597HER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\u4e2d\u7684\u6f5c\u5728\u4ef7\u503c TROPION-Breast02\u7814\u7a76\u6570\u636e\u5c06\u5c55\u793a\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u5728\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\u8fd9\u4e00\u6700\u5177\u4fb5\u88ad\u6027\u7684\u4e73\u817a\u764c\u5206\u578b\u4e2d\u7684\u6cbb\u7597\u6f5c\u529b POTOMAC\u7814\u7a76\u7684\u65e0\u75c5\u751f\u5b58\u671f\u6570\u636e\u4e0eMATTERHORN\u7814\u7a76\u7684\u751f\u5b58\u671f\u6570\u636e\u5c06\u5c55\u793a\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u5728\u65e9\u671f\u8180\u80f1\u764c\u4e0e\u80c3\u764c\u6cbb\u7597\u4e2d\u7684\u83b7\u76ca \u4e0a\u6d77 2025\u5e7410\u670814\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;\u00a0\u963f\u65af\u5229\u5eb7\u5c06\u4e8e2025\u5e7410\u670817\u65e5\u81f321\u65e5\u53ec\u5f00\u7684\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\u4e0a\uff0c\u51ed\u501f\u2f8f\u4e1a\u9886\u5148\u7684\u591a\u6837\u5316\u4ea7\u54c1\u4e0e\u7ba1\u7ebf\u5e03\u5c40\u7684\u5168\u65b0\u7814\u7a76\u6570\u636e\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u5176\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u683c\u5c40\u7684\u96c4\u5fc3\u58ee\u5fd7\u3002 \u672c\u6b21\u5927\u4f1a\u4e0a\uff0c\u963f\u65af\u5229\u5eb7\u5c06\u516c\u5e03\u903e95\u9879\u6458\u8981\uff0c\u6db5\u76d69\u6b3e\u5df2\u83b7\u5f97\u6279\u51c6\u836f\u7269\u53ca9\u6b3e\u6f5c\u5728\u65b0\u836f\uff0c\u5305\u62ec2\u9879\u5165\u9009\u91cd\u8981\u4e3b\u5e2d\u7814\u8ba8\u4f1a\uff08Presidential Symposium\uff09\u7684\u6458\u8981\u4ee5\u53ca26\u9879\u53e3\u5934\u62a5\u544a\u3002 \u5176\u4e2d\u4e3b\u8981\u4eae\u70b9\u5305\u62ec\uff1a DESTINY-Breast11\uff1a\u8bc4\u4f30\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u5e8f\u8d2fTHP\u65b9\u6848\uff08\u7d2b\u6749\u9187\u3001\u66f2\u59a5\u73e0\u5355\u6297\u53ca\u5e15\u59a5\u73e0\u5355\u6297\uff09\u7528\u4e8e\u9ad8\u98ce\u9669HER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\u65b0\u8f85\u52a9\u6cbb\u7597\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4e3b\u5e2d\u7814\u8ba8\u4f1a1\uff0c\u6458\u8981#291O\uff09\u3002 DESTINY-Breast05\uff1a\u8bc4\u4f30\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u7528\u4e8eHER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\uff08\u65b0\u8f85\u52a9\u6cbb\u7597\u540e\u5b58\u5728\u6b8b\u7559\u6d78\u6da6\u75c5\u7076\u5e76\u5177\u6709\u9ad8\u590d\u53d1\u98ce\u9669\uff09\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4e3b\u5e2d\u7814\u8ba8\u4f1a1\uff0c\u6458\u8981#LBA1\uff09\u3002\u00a0 TROPION-Breast02\uff1a\u8bc4\u4f30\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u7528\u4e8e\u4e00\u7ebf\u6cbb\u7597\u65e0\u6cd5\u63a5\u53d7\u514d\u75ab\u6cbb\u7597\u7684\u5c40\u90e8\u590d\u53d1\u6027\u4e0d\u53ef\u624b\u672f\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA21\uff09\u3002 POTOMAC \uff1a\u8bc4\u4f30\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408\u5361\u4ecb\u82d7\uff08BCG\uff09\u8bf1\u5bfc\u4e0e\u7ef4\u6301\u6cbb\u7597\uff0c\u7528\u4e8e\u9ad8\u5371\u975e\u808c\u5c42\u6d78\u6da6\u6027\u8180\u80f1\u764c\uff08NMIBC\uff09\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA108\uff09\u3002 MATTERHORN\uff1a\u516c\u5e03III\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u6700\u7ec8\u603b\u751f\u5b58\u671f\uff08OS\uff09\u7ed3\u679c\uff0c\u8bc4\u4f30\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408FLOT\u5316\u7597\u4f5c\u4e3a\u53ef\u5207\u9664\u7684\u65e9\u671f\u548c\u5c40\u90e8\u665a\u671f\u7684\u80c3\u548c\u80c3\u2edd\u7ba1\u7ed3\u5408\u90e8\u817a\u764c\uff08GEJ\uff09\u60a3\u8005\u56f4\u624b\u672f\u671f\u6cbb\u7597\u4e2d\u7684\u4e34\u5e8a\u83b7\u76ca\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA81\uff09\u3002 \u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\u3001\u5168\u7403\u80bf\u7624\u7814\u53d1\u8d1f\u8d23\u4eba\u9ad8\u4e66\u74a8\uff08Susan Galbraith\uff09\u8868\u793a\uff1a&#8221;\u6211\u4eec\u6b63\u52a0\u901f\u63a8\u8fdb\u591a\u5143\u521b\u65b0\u7597\u6cd5\u7ba1\u7ebf\uff0c\u4ee5\u53d8\u9769\u4e73\u817a\u764c\u60a3\u8005\u7684\u6cbb\u7597\u683c\u5c40\u3002\u5728\u672c\u5c4aESMO\u5927\u4f1a\u4e0a\uff0c\u6211\u4eec\u5c06\u516c\u5e03TROPION-Breast02\u3001DESTINY-Breast11\u548cDESTINY-Breast05\u7814\u7a76\u7684\u6570\u636e\u548c\u91cd\u8981\u8fdb\u5c55\u3002\u540c\u65f6\uff0c\u6211\u4eec\u4e5f\u5c06\u5c55\u793a\u65b0\u4e00\u4ee3\u6f5c\u5728\u6297\u80bf\u7624\u65b0\u836f\u7684\u6570\u636e\uff0c\u5305\u62ecsaruparib\u8054\u5408\u65b0\u578b\u6fc0\u7d20\u7597\u6cd5\u7528\u4e8e\u524d\u5217\u817a\u764c\u9886\u57df\uff0c\u9776\u5411\u53f6\u9178\u53d7\u4f53\u7684\u6297\u4f53\u5076\u8054\u836f\u7269torvu-sam\u7528\u4e8e\u5375\u5de2\u764c\u9886\u57df\uff0c\u4ee5\u53carilvegostomig\u7528\u4e8e\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u9886\u57df\u3002&#8221; \u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\uff0c\u80bf\u7624\u4e1a\u52a1\u8d1f\u8d23\u4ebaDave Fredrickson\u8868\u793a\uff1a&#8221;\u6211\u4eec\u4e1a\u754c\u9886\u5148\u7684\u80bf\u7624\u4ea7\u54c1\u7ec4\u5408\u5728\u672c\u6b21ESMO\u6301\u7eed\u5c55\u73b0\u5f3a\u52b2\u52bf\u5934\uff0c\u9996\u6b21\u516c\u5e03\u4e86\u56db\u9879\u5173\u952e\u7814\u7a76\u7684\u6570\u636e\u3002\u5176\u4e2d\uff0c\u4e0d\u4ec5\u6709\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u548c\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u5728\u4e73\u817a\u764c\u9886\u57df\u7684\u91cd\u5927\u8fdb\u5c55\uff0c\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u7684POTOMAC\u8bd5\u9a8c\u7ed3\u679c\u4e5f\u8bc1\u660e\u4e86\u514d\u75ab\u7597\u6cd5\u4e3a\u65e9\u671f\u8180\u80f1\u764c\u6cbb\u7597\u5e26\u6765\u7684\u76ca\u5904\uff0c\u8fdb\u800c\u9610\u91ca\u6211\u4eec\u7684\u7b56\u7565\u2014\u2014\u5c06\u524d\u6cbf\u6cbb\u7597\u5f15\u5165\u764c\u75c7\u65e9\u671f\u8fd9\u4e00\u60a3\u8005\u6700\u80fd\u591f\u83b7\u76ca\u7684\u9636\u6bb5\u3002&#8221; \u5176\u4ed6\u4eae\u70b9\u5305\u62ec\uff1a FONTANA\uff1a\u8bc4\u4f30\u9776\u5411\u53f6\u9178\u53d7\u4f53\u03b1\uff08FR\u03b1\uff09\u7684\u6297\u4f53\u836f\u7269\u5076\u8054\u7269AZD5335\u7528\u4e8e\u94c2\u8010\u836f\u590d\u53d1\u6027\u5375\u5de2\u764c\u60a3\u8005\u7684I\/IIa\u671f\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u8bd5\u9a8c\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#1065MO\uff09\u3002 PETRANHA\uff1a\u8bc4\u4f30saruparib\u8054\u5408\u96c4\u6fc0\u7d20\u53d7\u4f53\u901a\u8def\u6291\u5236\u5242\u7528\u4e8e\u6cbb\u7597\u8f6c\u79fb\u6027\u524d\u5217\u817a\u764c\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#2384MO\uff09\u3002 ARTEMIDE -01\uff1a\u8bc4\u4f30rilvegostomig\u7528\u4e8e\u68c0\u67e5\u70b9\u6291\u5236\u5242\u521d\u6cbb\u7684\u8f6c\u79fb\u6027\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#1853MO\uff09\u3002 FLAURA2\uff1a\u5728\u5965\u5e0c\u66ff\u5c3c\u5408\u5316\u7597\u6cbb\u7597\u665a\u671fEGFR\u7a81\u53d8NSCLC\u60a3\u8005\u7684FLAURA2 III\u671f\u4e34\u5e8a\u7814\u7a76\u4e2d\u5b58\u5728\u4e0d\u826f\u9884\u540e\u56e0\u7d20\u60a3\u8005\u7684\u63a2\u7d22\u6027OS\u5206\u6790\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA77\uff09\u3002 CAPItello -281\uff1a\u5361\u5339\u8272\u66ff\u8054\u5408\u963f\u6bd4\u7279\u9f99\u548c\u96c4\u6fc0\u7d20\u5265\u593a\u7597\u6cd5\uff08ADT\uff09\u7528\u4e8ePTEN\u7f3a\u9677\u7684\u65b0\u53d1\u8f6c\u79fb\u6027\u6fc0\u7d20\u654f\u611f\u6027\u524d\u5217\u817a\u764c\uff08mHSPC\uff09\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#2383O\uff09\u3002 TROPION -PanTumor03\uff1a\u8bc4\u4f30\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u8054\u5408rilvegostomig\u6cbb\u7597\u5c40\u665a\u671f\u6216\u8f6c\u79fb\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\uff08a\/mUC\uff09\u60a3\u8005\u7684\u7597\u6548\uff1a II\u671fTROPION-PanTumor03\u7814\u7a76\u7ed3\u679c\u7ed3\u679c\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981 #3072MO\uff09 BEGONIA \uff1a\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u8054\u5408\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u7528\u4e8e\u65e2\u5f80\u672a\u7ecf\u6cbb\u7597\u7684\u4e0d\u53ef\u5207\u9664\u3001\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u60a3\u8005\u7684BEGONIA Ib\/II\u671f\u8bd5\u9a8c\u6700\u7ec8\u7ed3\u679c\uff08\u53e3\u5934\u62a5\u544a\u6458\u8981#555MO\uff09\u3002 \u963f\u65af\u5229\u5eb7\u4e0e\u7b2c\u2f00\u4e09\u5171\u8054\u5408\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u4e0e\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\uff1b\u4e0e\u9ed8\u6c99\u4e1c\uff08\u9ed8\u6c99\u4e1c\u662f\u7f8e\u56fd\u65b0\u6cfd\u897f\u5dde\u7f57\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u516c\u53f8\u5546\u53f7\uff09\u8054\u5408\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u5965\u62c9\u5e15\u5229\uff1b\u4e0e\u548c\u9ec4\u533b\u836f\u5408\u4f5c\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u8d5b\u6c83\u66ff\u5c3c\u3002Rilvegostomig\u662f\u4e00\u79cd\u9776\u5411PD-1\u548cTIGIT\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff0c\u5176\u4e2dTIGIT\u90e8\u5206\u6e90\u81eaCompugen\u516c\u53f8\u4e34\u5e8a\u9636\u6bb5\u7684\u6297TIGIT\u6297\u4f53COM902\u3002 \u963f\u65af\u5229\u5eb7\u57282025\u5e74ESMO\u5e74\u4f1a\u671f\u95f4\u7684\u91cd\u8981\u6f14\u8bb2[1] \u4e3b\u8981\u4f5c\u8005 \u6458\u8981\u6807\u9898 \u62a5\u544a\u8be6\u60c5(CEST) \u6297\u4f53\u5076\u8054\u836f\u7269 Harbeck, N DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/moneycompass.com.my\/cn\/\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\/\" \/>\n<meta property=\"og:site_name\" content=\"Money Compass CN\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-14T13:00:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/\",\"name\":\"\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3 - Money Compass CN\",\"isPartOf\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/10\/image-FgrtK3.jpeg\",\"datePublished\":\"2025-10-14T13:00:00+00:00\",\"dateModified\":\"2025-10-14T13:00:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#primaryimage\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/10\/image-FgrtK3.jpeg\",\"contentUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/10\/image-FgrtK3.jpeg\",\"width\":144,\"height\":61},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/moneycompass.com.my\/cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/\",\"name\":\"Money Compass CN\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3 - Money Compass CN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/moneycompass.com.my\/cn\/\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\/","og_locale":"en_US","og_type":"article","og_title":"\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3 - Money Compass CN","og_description":"DESTINY-Breast11\u4e0eDESTINY-Breast05\u4e24\u9879\u7814\u7a76\u5165\u9009\u4e3b\u5e2d\u7814\u8ba8\u4f1a\uff08Presidential Symposium\uff09\uff0c\u51f8\u663e\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u5728\u6cbb\u7597HER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\u4e2d\u7684\u6f5c\u5728\u4ef7\u503c TROPION-Breast02\u7814\u7a76\u6570\u636e\u5c06\u5c55\u793a\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u5728\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\u8fd9\u4e00\u6700\u5177\u4fb5\u88ad\u6027\u7684\u4e73\u817a\u764c\u5206\u578b\u4e2d\u7684\u6cbb\u7597\u6f5c\u529b POTOMAC\u7814\u7a76\u7684\u65e0\u75c5\u751f\u5b58\u671f\u6570\u636e\u4e0eMATTERHORN\u7814\u7a76\u7684\u751f\u5b58\u671f\u6570\u636e\u5c06\u5c55\u793a\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u5728\u65e9\u671f\u8180\u80f1\u764c\u4e0e\u80c3\u764c\u6cbb\u7597\u4e2d\u7684\u83b7\u76ca \u4e0a\u6d77 2025\u5e7410\u670814\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;\u00a0\u963f\u65af\u5229\u5eb7\u5c06\u4e8e2025\u5e7410\u670817\u65e5\u81f321\u65e5\u53ec\u5f00\u7684\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\u4e0a\uff0c\u51ed\u501f\u2f8f\u4e1a\u9886\u5148\u7684\u591a\u6837\u5316\u4ea7\u54c1\u4e0e\u7ba1\u7ebf\u5e03\u5c40\u7684\u5168\u65b0\u7814\u7a76\u6570\u636e\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u5176\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u683c\u5c40\u7684\u96c4\u5fc3\u58ee\u5fd7\u3002 \u672c\u6b21\u5927\u4f1a\u4e0a\uff0c\u963f\u65af\u5229\u5eb7\u5c06\u516c\u5e03\u903e95\u9879\u6458\u8981\uff0c\u6db5\u76d69\u6b3e\u5df2\u83b7\u5f97\u6279\u51c6\u836f\u7269\u53ca9\u6b3e\u6f5c\u5728\u65b0\u836f\uff0c\u5305\u62ec2\u9879\u5165\u9009\u91cd\u8981\u4e3b\u5e2d\u7814\u8ba8\u4f1a\uff08Presidential Symposium\uff09\u7684\u6458\u8981\u4ee5\u53ca26\u9879\u53e3\u5934\u62a5\u544a\u3002 \u5176\u4e2d\u4e3b\u8981\u4eae\u70b9\u5305\u62ec\uff1a DESTINY-Breast11\uff1a\u8bc4\u4f30\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u5e8f\u8d2fTHP\u65b9\u6848\uff08\u7d2b\u6749\u9187\u3001\u66f2\u59a5\u73e0\u5355\u6297\u53ca\u5e15\u59a5\u73e0\u5355\u6297\uff09\u7528\u4e8e\u9ad8\u98ce\u9669HER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\u65b0\u8f85\u52a9\u6cbb\u7597\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4e3b\u5e2d\u7814\u8ba8\u4f1a1\uff0c\u6458\u8981#291O\uff09\u3002 DESTINY-Breast05\uff1a\u8bc4\u4f30\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u7528\u4e8eHER2\u9633\u6027\u65e9\u671f\u4e73\u817a\u764c\uff08\u65b0\u8f85\u52a9\u6cbb\u7597\u540e\u5b58\u5728\u6b8b\u7559\u6d78\u6da6\u75c5\u7076\u5e76\u5177\u6709\u9ad8\u590d\u53d1\u98ce\u9669\uff09\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4e3b\u5e2d\u7814\u8ba8\u4f1a1\uff0c\u6458\u8981#LBA1\uff09\u3002\u00a0 TROPION-Breast02\uff1a\u8bc4\u4f30\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u7528\u4e8e\u4e00\u7ebf\u6cbb\u7597\u65e0\u6cd5\u63a5\u53d7\u514d\u75ab\u6cbb\u7597\u7684\u5c40\u90e8\u590d\u53d1\u6027\u4e0d\u53ef\u624b\u672f\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA21\uff09\u3002 POTOMAC \uff1a\u8bc4\u4f30\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408\u5361\u4ecb\u82d7\uff08BCG\uff09\u8bf1\u5bfc\u4e0e\u7ef4\u6301\u6cbb\u7597\uff0c\u7528\u4e8e\u9ad8\u5371\u975e\u808c\u5c42\u6d78\u6da6\u6027\u8180\u80f1\u764c\uff08NMIBC\uff09\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA108\uff09\u3002 MATTERHORN\uff1a\u516c\u5e03III\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u6700\u7ec8\u603b\u751f\u5b58\u671f\uff08OS\uff09\u7ed3\u679c\uff0c\u8bc4\u4f30\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408FLOT\u5316\u7597\u4f5c\u4e3a\u53ef\u5207\u9664\u7684\u65e9\u671f\u548c\u5c40\u90e8\u665a\u671f\u7684\u80c3\u548c\u80c3\u2edd\u7ba1\u7ed3\u5408\u90e8\u817a\u764c\uff08GEJ\uff09\u60a3\u8005\u56f4\u624b\u672f\u671f\u6cbb\u7597\u4e2d\u7684\u4e34\u5e8a\u83b7\u76ca\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA81\uff09\u3002 \u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\u3001\u5168\u7403\u80bf\u7624\u7814\u53d1\u8d1f\u8d23\u4eba\u9ad8\u4e66\u74a8\uff08Susan Galbraith\uff09\u8868\u793a\uff1a&#8221;\u6211\u4eec\u6b63\u52a0\u901f\u63a8\u8fdb\u591a\u5143\u521b\u65b0\u7597\u6cd5\u7ba1\u7ebf\uff0c\u4ee5\u53d8\u9769\u4e73\u817a\u764c\u60a3\u8005\u7684\u6cbb\u7597\u683c\u5c40\u3002\u5728\u672c\u5c4aESMO\u5927\u4f1a\u4e0a\uff0c\u6211\u4eec\u5c06\u516c\u5e03TROPION-Breast02\u3001DESTINY-Breast11\u548cDESTINY-Breast05\u7814\u7a76\u7684\u6570\u636e\u548c\u91cd\u8981\u8fdb\u5c55\u3002\u540c\u65f6\uff0c\u6211\u4eec\u4e5f\u5c06\u5c55\u793a\u65b0\u4e00\u4ee3\u6f5c\u5728\u6297\u80bf\u7624\u65b0\u836f\u7684\u6570\u636e\uff0c\u5305\u62ecsaruparib\u8054\u5408\u65b0\u578b\u6fc0\u7d20\u7597\u6cd5\u7528\u4e8e\u524d\u5217\u817a\u764c\u9886\u57df\uff0c\u9776\u5411\u53f6\u9178\u53d7\u4f53\u7684\u6297\u4f53\u5076\u8054\u836f\u7269torvu-sam\u7528\u4e8e\u5375\u5de2\u764c\u9886\u57df\uff0c\u4ee5\u53carilvegostomig\u7528\u4e8e\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u9886\u57df\u3002&#8221; \u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\uff0c\u80bf\u7624\u4e1a\u52a1\u8d1f\u8d23\u4ebaDave Fredrickson\u8868\u793a\uff1a&#8221;\u6211\u4eec\u4e1a\u754c\u9886\u5148\u7684\u80bf\u7624\u4ea7\u54c1\u7ec4\u5408\u5728\u672c\u6b21ESMO\u6301\u7eed\u5c55\u73b0\u5f3a\u52b2\u52bf\u5934\uff0c\u9996\u6b21\u516c\u5e03\u4e86\u56db\u9879\u5173\u952e\u7814\u7a76\u7684\u6570\u636e\u3002\u5176\u4e2d\uff0c\u4e0d\u4ec5\u6709\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u548c\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u5728\u4e73\u817a\u764c\u9886\u57df\u7684\u91cd\u5927\u8fdb\u5c55\uff0c\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u7684POTOMAC\u8bd5\u9a8c\u7ed3\u679c\u4e5f\u8bc1\u660e\u4e86\u514d\u75ab\u7597\u6cd5\u4e3a\u65e9\u671f\u8180\u80f1\u764c\u6cbb\u7597\u5e26\u6765\u7684\u76ca\u5904\uff0c\u8fdb\u800c\u9610\u91ca\u6211\u4eec\u7684\u7b56\u7565\u2014\u2014\u5c06\u524d\u6cbf\u6cbb\u7597\u5f15\u5165\u764c\u75c7\u65e9\u671f\u8fd9\u4e00\u60a3\u8005\u6700\u80fd\u591f\u83b7\u76ca\u7684\u9636\u6bb5\u3002&#8221; \u5176\u4ed6\u4eae\u70b9\u5305\u62ec\uff1a FONTANA\uff1a\u8bc4\u4f30\u9776\u5411\u53f6\u9178\u53d7\u4f53\u03b1\uff08FR\u03b1\uff09\u7684\u6297\u4f53\u836f\u7269\u5076\u8054\u7269AZD5335\u7528\u4e8e\u94c2\u8010\u836f\u590d\u53d1\u6027\u5375\u5de2\u764c\u60a3\u8005\u7684I\/IIa\u671f\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u8bd5\u9a8c\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#1065MO\uff09\u3002 PETRANHA\uff1a\u8bc4\u4f30saruparib\u8054\u5408\u96c4\u6fc0\u7d20\u53d7\u4f53\u901a\u8def\u6291\u5236\u5242\u7528\u4e8e\u6cbb\u7597\u8f6c\u79fb\u6027\u524d\u5217\u817a\u764c\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#2384MO\uff09\u3002 ARTEMIDE -01\uff1a\u8bc4\u4f30rilvegostomig\u7528\u4e8e\u68c0\u67e5\u70b9\u6291\u5236\u5242\u521d\u6cbb\u7684\u8f6c\u79fb\u6027\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981#1853MO\uff09\u3002 FLAURA2\uff1a\u5728\u5965\u5e0c\u66ff\u5c3c\u5408\u5316\u7597\u6cbb\u7597\u665a\u671fEGFR\u7a81\u53d8NSCLC\u60a3\u8005\u7684FLAURA2 III\u671f\u4e34\u5e8a\u7814\u7a76\u4e2d\u5b58\u5728\u4e0d\u826f\u9884\u540e\u56e0\u7d20\u60a3\u8005\u7684\u63a2\u7d22\u6027OS\u5206\u6790\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#LBA77\uff09\u3002 CAPItello -281\uff1a\u5361\u5339\u8272\u66ff\u8054\u5408\u963f\u6bd4\u7279\u9f99\u548c\u96c4\u6fc0\u7d20\u5265\u593a\u7597\u6cd5\uff08ADT\uff09\u7528\u4e8ePTEN\u7f3a\u9677\u7684\u65b0\u53d1\u8f6c\u79fb\u6027\u6fc0\u7d20\u654f\u611f\u6027\u524d\u5217\u817a\u764c\uff08mHSPC\uff09\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u4f18\u9009\u8bba\u6587\u6458\u8981#2383O\uff09\u3002 TROPION -PanTumor03\uff1a\u8bc4\u4f30\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u8054\u5408rilvegostomig\u6cbb\u7597\u5c40\u665a\u671f\u6216\u8f6c\u79fb\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\uff08a\/mUC\uff09\u60a3\u8005\u7684\u7597\u6548\uff1a II\u671fTROPION-PanTumor03\u7814\u7a76\u7ed3\u679c\u7ed3\u679c\uff08\u7b80\u77ed\u53e3\u5934\u62a5\u544a\u6458\u8981 #3072MO\uff09 BEGONIA \uff1a\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\u8054\u5408\u5ea6\u4f10\u5229\u5c24\u5355\u6297\u7528\u4e8e\u65e2\u5f80\u672a\u7ecf\u6cbb\u7597\u7684\u4e0d\u53ef\u5207\u9664\u3001\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u60a3\u8005\u7684BEGONIA Ib\/II\u671f\u8bd5\u9a8c\u6700\u7ec8\u7ed3\u679c\uff08\u53e3\u5934\u62a5\u544a\u6458\u8981#555MO\uff09\u3002 \u963f\u65af\u5229\u5eb7\u4e0e\u7b2c\u2f00\u4e09\u5171\u8054\u5408\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u4e0e\u5fb7\u8fbe\u535a\u59a5\u5355\u6297\uff1b\u4e0e\u9ed8\u6c99\u4e1c\uff08\u9ed8\u6c99\u4e1c\u662f\u7f8e\u56fd\u65b0\u6cfd\u897f\u5dde\u7f57\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u516c\u53f8\u5546\u53f7\uff09\u8054\u5408\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u5965\u62c9\u5e15\u5229\uff1b\u4e0e\u548c\u9ec4\u533b\u836f\u5408\u4f5c\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u8d5b\u6c83\u66ff\u5c3c\u3002Rilvegostomig\u662f\u4e00\u79cd\u9776\u5411PD-1\u548cTIGIT\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff0c\u5176\u4e2dTIGIT\u90e8\u5206\u6e90\u81eaCompugen\u516c\u53f8\u4e34\u5e8a\u9636\u6bb5\u7684\u6297TIGIT\u6297\u4f53COM902\u3002 \u963f\u65af\u5229\u5eb7\u57282025\u5e74ESMO\u5e74\u4f1a\u671f\u95f4\u7684\u91cd\u8981\u6f14\u8bb2[1] \u4e3b\u8981\u4f5c\u8005 \u6458\u8981\u6807\u9898 \u62a5\u544a\u8be6\u60c5(CEST) \u6297\u4f53\u5076\u8054\u836f\u7269 Harbeck, N DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel [&hellip;]","og_url":"https:\/\/moneycompass.com.my\/cn\/\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\/","og_site_name":"Money Compass CN","article_published_time":"2025-10-14T13:00:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/","url":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/","name":"\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3 - Money Compass CN","isPartOf":{"@id":"https:\/\/moneycompass.com.my\/cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#primaryimage"},"image":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#primaryimage"},"thumbnailUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/10\/image-FgrtK3.jpeg","datePublished":"2025-10-14T13:00:00+00:00","dateModified":"2025-10-14T13:00:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#primaryimage","url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/10\/image-FgrtK3.jpeg","contentUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/10\/image-FgrtK3.jpeg","width":144,"height":61},{"@type":"BreadcrumbList","@id":"https:\/\/moneycompass.com.my\/cn\/%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e6%90%ba%e5%9b%9b%e9%a1%b9%e9%87%8d%e8%a6%81%e7%a0%94%e7%a9%b6%e9%a6%96%e5%8f%91%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%e6%ac%a7%e6%b4%b2%e8%82%bf%e7%98%a4%e5%86%85\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/moneycompass.com.my\/cn\/"},{"@type":"ListItem","position":2,"name":"\u963f\u65af\u5229\u5eb7\u643a\u56db\u9879\u91cd\u8981\u7814\u7a76\u9996\u53d1\u6570\u636e\u4eae\u76f8\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\uff0c\u8fdb\u4e00\u6b65\u5f70\u663e\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u7684\u96c4\u5fc3"}]},{"@type":"WebSite","@id":"https:\/\/moneycompass.com.my\/cn\/#website","url":"https:\/\/moneycompass.com.my\/cn\/","name":"Money Compass CN","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/16864"}],"collection":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/comments?post=16864"}],"version-history":[{"count":0,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/16864\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media\/16865"}],"wp:attachment":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media?parent=16864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/categories?post=16864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/tags?post=16864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}